Get the Stockscreener App
0.193
1.15%
0.0022
Lyra Therapeutics Inc stock is traded at $0.193, with a volume of 824.86K.
It is up +1.15% in the last 24 hours and down -10.77% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$0.1908
Open:
$0.1901
24h Volume:
824.86K
Relative Volume:
0.49
Market Cap:
$12.49M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-0.1295
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
+5.58%
1M Performance:
-10.77%
6M Performance:
-36.97%
1Y Performance:
-96.06%
1-Day Range:
$0.189
$0.1989
1-Week Range:
$0.1785
$0.1989
52-Week Range:
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.193 | 12.49M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics Inc (LYRA) Shares Rise Despite Market Challenges - The News Heater
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
LYRA News Today | Why did Lyra Therapeutics stock go up today? - MarketBeat
Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register
Data-Based Insights About Mister Car Wash Inc (MCW) - Stocks Register
Open Lending Corp’s (LPRO) Stock Is Harder To Predict Than You Think - Stocks Register
There Is A Lot Of Upside Potential For Helius Medical Technologies Inc(NASDAQ: HSDT) - Stocks Register
New Outlook On Vestis Corp - Stocks Register
Cadiz Inc (CDZI): An Important Analyst Insights - Stocks Register
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics - openPR
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Are Investors Keen On Selling Holdings In Phoenix Motor Inc (NASDAQ: PEV)? - Stocks Register
State Street Corp Takes Position in Lotus Technology Inc. (NASDAQ:LOT) - Defense World
State Street Corp Has $126,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Edible Garden AG Inc (NASDAQ: EDBL): A Stock Worth Watching - Stocks Register
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
Lyra Therapeutics reshuffles board, adjusts director classes - Investing.com
Lyra Therapeutics reshuffles board, adjusts director classes By Investing.com - Investing.com UK
Lyra Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lyra Therapeutics Inc’s (NASDAQ: LYRA) Stock Forecast: Increase To $0.5 In A Year - Stocks Register
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market Size was ~USD 3,930 Million in the 7MM in 2023, estimated DelveInsight - Barchart
Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings $1B Financing Track Record - StockTitan
LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
Kailera Therapeutics Launches with $400 Million Series A - GlobeNewswire
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):